COMMENTARY

• Chuikyo Moving toward Conclusion on Issue of Insurance Coverage for Heparinoid Drugs
  January 15, 2018

• Pricing Reform Could Goad Drug Makers to Focus Resources on PMP Hopefuls
  December 28, 2017

• Unraveling MHLW/MOF Tug-of-War on Drug Pricing Reform
  November 8, 2017

• With Study Group on Counterfeit Drugs to Resume Discussions this Fall, Full-Scale Discussions on Introduction of PIC/S GDP Guidelines Looming
  October 10, 2017

• Epigenetic Drug Discovery Efforts Expanding, with Solid Cancers Now Being Targeted
  September 1, 2017

• MHLW Panel Elaborating Rules for Clinical Research Law, “Scholarship Donations” to Be a Major Focus
  August 21, 2017

• Xarelto Survey Scandal Calls into Question Bayer’s Organizational Setup, Employee Ethics
  July 26, 2017

• Did Voice of the Industry Reach Honebuto Policymakers?
  June 21, 2017

• As AG Momentum Continues, Mucosta AG to Hit Shelves 8 Years after Gx Entry
  June 14, 2017

• MHLW, MOF Agreed on CEFP Working Group Report, Continuation of Premium As-Is Seems Difficult
  May 11, 2017

• Will Government Take the Lead in Pricing Debate towards 2017 Fiscal Blueprint?
  April 19, 2017

• “Cash-and-Carry Dealers” and Their Peculiar Business Practices in the Spotlight in Wake of Counterfeit Harvoni Scandal
  April 12, 2017

• Is the Government’s 70% Interim Generic Share Target Achievable?
  March 13, 2017

• Growing Hopes for Control of Hepatic Cancer; Road to Cures for Hepatitis B, NASH Might Be in Sight
  March 7, 2017

• Will NHI Pricing Reform in Sluggish Domestic Market Trigger Industry Reorganization?
  February 6, 2017

• Top-Notch Talents Needed for Pharma’s Lobbying Activities; Stay Current with Policymaking Moves
  January 30, 2017

• Hepatology Society Revises Hep C Treatment Guidelines; Looking to Future Research for Non-Responders to IFN-Free Treatment
  December 14, 2016

• Taltz Issue Exposes Forex-Sensitive Nature of Drug Pricing System
  November 15, 2016

• Are Biosimilars on Verge of Breakthrough in Japan? Initiatives Underway to Prepare for Full-Scale Entry of Major Biosimilars
  October 25, 2016

• Policymakers Face Balancing Act over Opdivo Re-Pricing
  October 17, 2016

ページ